Faropenem

Farom was launched in Japan for use as an antibiotic against common respiratory tract pathogens. It can be prepared by several related routes of about seven steps starting with tetrahydrofuran-2-thiocarboxylic acid and a silylated azetidinone. It is a broad spectrum oral penem antibiotic that is β-lactamase stable. Farom is the most active β-lactam against anaerobes (more than cefaclor, cefixime and amoxicillin) but also has activity against Gram-positive, Gram-negative and enterobacteriaceae. It is equally active against strains carrying plasmid and chromosome mediated β-lactamases. The short plasma elimination half-life is the result of hydrolysis by renal dehydropeptidase. It is more stable to hydrolysis by extended spectrum β-lactamases than some second and third generation cephalosporins.

Suntory (Japan)

Treatmentof bacterial infections.

Faropenem (cas# 106560-14-9) is a compound useful in organic synthesis.

ChEBI: 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid is a faropenem. It is a conjugate acid of a 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylate.

Farom

An orally active penem with a broad spectrum of antibacterial activity, including activity against selected anaerobic pathogens. Although it is active against most enterobacteria, it has reduced activity against Ser. marcescens, Enterobacter spp. and some Providencia spp. It generally retains activity against many Gram-positive organisms, but has no useful activity against Ps. aeruginosa. It has reduced activity against E. faecium, methicillin-resistant Staph. aureus (MRSA) and some strains of coagulase-negative staphylococci. It is stable to hydrolysis by extended spectrum β-lactamases, but is hydrolyzed by carbapenemases. Esterified prodrugs with increased bioavailability have been studied in clinical trials but have not received regulatory approval.